Abstract | AIM: METHODS: RESULTS: Eighty-four MAX, 179 TRACC and 69 NSWCC patients had peritoneal disease. There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts. Of the patients without peritoneal disease in the MAX trial, 4/300 (1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123 (0.8%) in the capecitabine alone arm. In the TRACC registry 3/126 (2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53 (1.9%) in the chemotherapy alone arm. In a further analysis of patients without peritoneal metastases in the TRACC registry, the rate of gastrointestinal perforations was 9/369 (2.4%) in the chemotherapy/ bevacizumab group and 5/177 (2.8%) in the chemotherapy alone group. The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts: MAX 6.9 m vs 4.9 m, HR = 0.64 (95%CI: 0.42-1.02); P = 0.063; TRACC 9.1 m vs 5.5 m, HR = 0.61 (95%CI: 0.37-0.86); P = 0.009; NSWCC 8.7 m vs 6.8 m, HR = 0.75 (95%CI: 0.43-1.32); P = 0.32. Chemotherapy duration was similar across the groups. CONCLUSION:
|
Authors | Aflah Roohullah, Hui-Li Wong, Katrin M Sjoquist, Peter Gibbs, Kathryn Field, Ben Tran, Jeremy Shapiro, Joe Mckendrick, Desmond Yip, Louise Nott, Val Gebski, Weng Ng, Wei Chua, Timothy Price, Niall Tebbutt, Lorraine Chantrill |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 21
Issue 17
Pg. 5352-8
(May 07 2015)
ISSN: 2219-2840 [Electronic] United States |
PMID | 25954110
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Bevacizumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Bevacizumab
(adverse effects)
- Clinical Trials, Phase III as Topic
- Colorectal Neoplasms
(drug therapy, mortality, pathology)
- Disease Progression
- Disease-Free Survival
- Female
- Humans
- Intestinal Perforation
(chemically induced, diagnosis)
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Peritoneal Neoplasms
(drug therapy, mortality, secondary)
- Randomized Controlled Trials as Topic
- Registries
- Risk Assessment
- Risk Factors
- Time Factors
- Treatment Outcome
- Young Adult
|